or use within 14 days of selegiline treatment is contraindicatedselegiline transdermalSerious - Use Alternative (1)selegiline transdermal and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.selinexorSerious - Use Alternative (1)selinexor, amoxapine. unspecified interaction mechanism. Avoid or Use Alternate Drug. Patients treated with selinexor may experience neurological toxicities. Avoid taking selinexor with other medications that may cause dizziness or confusion.selpercatinibMonitor Closely (1)selpercatinib increases toxicity of amoxapine by QTc interval. Use Caution/Monitor.serdexmethylphenidate/dexmethylphenidateSerious - Use Alternative (1)amoxapine, serdexmethylphenidate/dexmethylphenidate. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.Minor (1)serdexmethylphenidate/dexmethylphenidate increases effects of amoxapine by decreasing metabolism. Minor/Significance Unknown.sertralineMonitor Closely (1)sertraline and amoxapine both increase QTc interval. Use Caution/Monitor.Serious - Use Alternative (1)sertraline and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.sevofluraneMinor (1)sevoflurane, amoxapine. Mechanism: unspecified interaction mechanism. Minor/Significance Unknown. Risk of arrhythmias or hypotension.shepherd's purseMonitor Closely (1)amoxapine and shepherd's purse both increase sedation. Use Caution/Monitor.sitagliptinMinor (1)amoxapine increases effects of sitagliptin by pharmacodynamic synergism. Minor/Significance Unknown.sodium oxybateSerious - Use Alternative (1)amoxapine, sodium oxybate. Either increases effects of the other by pharmacodynamic synergism. Avoid or Use Alternate Drug. Profound sedation, respiratory depression, coma, and death may result if coadministered. Reserve concomitant prescribing of these drugs in patients for whom other treatment options are inadequate. Limit dosages and durations to the minimum required. Monitor closely for signs of respiratory depression and sedation.sodium sulfate/?magnesium sulfate/potassium chlorideMonitor Closely (1)sodium sulfate/?magnesium sulfate/potassium chloride increases effects of amoxapine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycolMonitor Closely (1)amoxapine, sodium sulfate/potassium chloride/magnesium sulfate/polyethylene glycol. Other (see comment). Use Caution/Monitor. Comment: Caution when bowel preps are used with drugs that cause SIADH or NSAIDs; increased risk for water retention or electrolyte imbalance.sodium sulfate/potassium sulfate/magnesium sulfateMonitor Closely (1)sodium sulfate/potassium sulfate/magnesium sulfate increases effects of amoxapine by unknown mechanism. Use Caution/Monitor. Closely monitor for evidence of seizures when using higher dose of magnesium sulfate together with drugs that lower the seizure threshold.solifenacinMonitor Closely (2)solifenacin and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor. solifenacin and amoxapine both increase QTc interval. Use Caution/Monitor.sorafenibMonitor Closely (1)sorafenib and amoxapine both increase QTc interval. Use Caution/Monitor.sotalolContraindicated (1)amoxapine and sotalol both increase QTc interval. Contraindicated.St John's WortSerious - Use Alternative (1)amoxapine and St John's Wort both increase serotonin levels. Avoid or Use Alternate Drug.stiripentolMonitor Closely (1)stiripentol, amoxapine. Either increases effects of the other by sedation. Use Caution/Monitor. Concomitant use stiripentol with other CNS depressants, including alcohol, may increase the risk of sedation and somnolence.succinylcholineMonitor Closely (1)succinylcholine increases and amoxapine decreases cholinergic effects/transmission. Effect of interaction is not clear, use caution. Use Caution/Monitor.sufentanilMonitor Closely (1)sufentanil and amoxapine both increase sedation. Use Caution/Monitor.sufentanil SLMonitor Closely (1)sufentanil SL, amoxapine. Either increases effects of the other by serotonin levels. Use Caution/Monitor. Coadministration of drugs that affect the serotonergic neurotransmitter system may result in serotonin syndrome. If concomitant use is warranted, carefully observe the patient, particularly during treatment initiation and dose adjustment.sulfamethoxazoleMonitor Closely (1)amoxapine and sulfamethoxazole both increase QTc interval. Modify Therapy/Monitor Closely.Minor (1)sulfamethoxazole decreases levels of amoxapine by unspecified interaction mechanism. Minor/Significance Unknown.sumatriptanMonitor Closely (1)sumatriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.sumatriptan intranasalMonitor Closely (1)sumatriptan intranasal and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.suvorexantMonitor Closely (1)suvorexant and amoxapine both increase sedation. Modify Therapy/Monitor Closely. Dosage adjustments of suvorexant and concomitant CNS depressants may be necessarytapentadolMonitor Closely (2)amoxapine and tapentadol both increase serotonin levels. Modify Therapy/Monitor Closely. tapentadol and amoxapine both increase sedation. Use Caution/Monitor.tedizolidSerious - Use Alternative (1)tedizolid, amoxapine. Either increases effects of the other by Mechanism: pharmacodynamic synergism. Avoid or Use Alternate Drug. both increase serotonin levels; increased risk of serotonin syndrome.telavancinMonitor Closely (1)amoxapine and telavancin both increase QTc interval. Modify Therapy/Monitor Closely.temazepamMonitor Closely (1)temazepam and amoxapine both increase sedation. Use Caution/Monitor.terbinafineMonitor Closely (1)terbinafine will increase the level or effect of amoxapine by affecting hepatic enzyme CYP2D6 metabolism. Modify Therapy/Monitor Closely. Assess need to reduce dose of CYP2D6-metabolized drug.terbutalineMonitor Closely (1)amoxapine increases and terbutaline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)amoxapine, terbutaline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.tetrabenazineMonitor Closely (1)amoxapine and tetrabenazine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely.thioridazineMonitor Closely (2)thioridazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. thioridazine and amoxapine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)thioridazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)amoxapine, thioridazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. amoxapine, thioridazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.thiothixeneMonitor Closely (2)thiothixene and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Use Caution/Monitor. thiothixene and amoxapine both increase sedation. Use Caution/Monitor.thyroid desiccatedMonitor Closely (1)thyroid desiccated increases effects of amoxapine by Other (see comment). Use Caution/Monitor. Comment: Increased catecholamine receptor sensitivity; may increase CNS and cardiovascular effects, including arrhythmias.tiotropiumMonitor Closely (1)tiotropium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.tolazamideMinor (1)amoxapine increases effects of tolazamide by pharmacodynamic synergism. Minor/Significance Unknown.tolbutamideMinor (1)amoxapine increases effects of tolbutamide by pharmacodynamic synergism. Minor/Significance Unknown.tolterodineMonitor Closely (1)tolterodine and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.topiramateMonitor Closely (1)amoxapine and topiramate both increase sedation. Modify Therapy/Monitor Closely.tramadolMonitor Closely (2)amoxapine and tramadol both increase serotonin levels. Modify Therapy/Monitor Closely. tramadol and amoxapine both increase sedation. Use Caution/Monitor.tranylcypromineContraindicated (1)tranylcypromine and amoxapine both increase serotonin levels. Contraindicated.trazodoneMonitor Closely (2)amoxapine and trazodone both decrease cholinergic effects/transmission. Use Caution/Monitor. amoxapine and trazodone both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amoxapine and trazodone both increase QTc interval. Avoid or Use Alternate Drug. trazodone and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.triazolamMonitor Closely (1)triazolam and amoxapine both increase sedation. Use Caution/Monitor.triclofosMonitor Closely (1)triclofos and amoxapine both increase sedation. Use Caution/Monitor.trifluoperazineMonitor Closely (2)trifluoperazine and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Modify Therapy/Monitor Closely. trifluoperazine and amoxapine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)trifluoperazine and amoxapine both increase QTc interval. Avoid or Use Alternate Drug.Minor (2)amoxapine, trifluoperazine. Either increases levels of the other by decreasing metabolism. Minor/Significance Unknown. Additive anticholinergic effects. amoxapine, trifluoperazine. Either increases levels of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive anticholinergic effects.trihexyphenidylMonitor Closely (1)trihexyphenidyl and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor. Potential for additive anticholinergic effects.trimethoprimMonitor Closely (1)amoxapine and trimethoprim both increase QTc interval. Modify Therapy/Monitor Closely.trimipramineMonitor Closely (2)amoxapine and trimipramine both decrease cholinergic effects/transmission. Use Caution/Monitor. amoxapine and trimipramine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (2)amoxapine and trimipramine both increase QTc interval. Avoid or Use Alternate Drug. amoxapine and trimipramine both increase serotonin levels. Avoid or Use Alternate Drug.triprolidineMonitor Closely (1)triprolidine and amoxapine both increase sedation. Use Caution/Monitor.tropisetronMonitor Closely (1)amoxapine and tropisetron both increase QTc interval. Modify Therapy/Monitor Closely.trospium chlorideMonitor Closely (1)trospium chloride and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.umeclidinium bromide/vilanterol inhaledSerious - Use Alternative (2)amoxapine increases toxicity of umeclidinium bromide/vilanterol inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated. amoxapine and umeclidinium bromide/vilanterol inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiatedvalbenazineMonitor Closely (1)valbenazine and amoxapine both increase QTc interval. Use Caution/Monitor.valerianMonitor Closely (1)valerian and amoxapine both increase sedation. Use Caution/Monitor.vandetanibSerious - Use Alternative (1)amoxapine, vandetanib. Either increases toxicity of the other by QTc interval. Avoid or Use Alternate Drug. Avoid coadministration with drugs known to prolong QT interval; if a drug known to prolong QT interval must be used, more frequent ECG monitoring is recommended.vasopressinMinor (1)amoxapine increases effects of vasopressin by pharmacodynamic synergism. Minor/Significance Unknown.vecuroniumMonitor Closely (1)vecuronium and amoxapine both decrease cholinergic effects/transmission. Use Caution/Monitor.vemurafenibSerious - Use Alternative (1)vemurafenib and amoxapine both increase QTc interval. Avoid or Use Alternate Drug. Concomitant use of vemurafenib with drugs that prolong QT interval is not recommended.venlafaxineMonitor Closely (1)amoxapine and venlafaxine both increase QTc interval. Modify Therapy/Monitor Closely.Serious - Use Alternative (1)venlafaxine and amoxapine both increase serotonin levels. Avoid or Use Alternate Drug.verapamilMinor (1)verapamil increases levels of amoxapine by decreasing metabolism. Minor/Significance Unknown.vilanterol/fluticasone furoate inhaledSerious - Use Alternative (2)amoxapine and vilanterol/fluticasone furoate inhaled both increase sympathetic (adrenergic) effects, including increased blood pressure and heart rate. Avoid or Use Alternate Drug. Exercise extreme caution if vilanterol coadministered with MAOIs or TCAs, or within 2 weeks of discontinuation of these drugs; adrenergic agonist effects on the cardiovascular system may be potentiated amoxapine increases toxicity of vilanterol/fluticasone furoate inhaled by QTc interval. Avoid or Use Alternate Drug. Exercise extreme caution when vilanterol coadministered with drugs that prolong QTc interval; adrenergic agonist effects on the cardiovascular system may be potentiated.vildagliptinMinor (1)amoxapine increases effects of vildagliptin by pharmacodynamic synergism. Minor/Significance Unknown.voclosporinMonitor Closely (1)voclosporin, amoxapine. Either increases effects of the other by QTc interval. Use Caution/Monitor.voriconazoleMonitor Closely (1)amoxapine and voriconazole both increase QTc interval. Modify Therapy/Monitor Closely.vortioxetineSerious - Use Alternative (1)amoxapine, vortioxetine. Either increases effects of the other by serotonin levels. Avoid or Use Alternate Drug.xylometazolineMonitor Closely (1)amoxapine increases and xylometazoline decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)amoxapine, xylometazoline. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.yohimbeSerious - Use Alternative (1)yohimbe, amoxapine. Mechanism: unspecified interaction mechanism. Contraindicated. May cause increase or decrease in blood pressure.yohimbineMonitor Closely (1)amoxapine increases and yohimbine decreases sedation. Effect of interaction is not clear, use caution. Use Caution/Monitor.Serious - Use Alternative (1)amoxapine, yohimbine. Other (see comment). Avoid or Use Alternate Drug. Comment: Tricyclic antidepressants increase or decrease effects of sympathomimetics, by blocking reuptake of NE, or blocking uptake of indirect sympathomimetics into the adrenergic neuron.ziconotideMonitor Closely (1)amoxapine and ziconotide both increase sedation. Use Caution/Monitor.ziprasidoneContraindicated (1)ziprasidone and amoxapine both increase antidopaminergic effects, including extrapyramidal symptoms and neuroleptic malignant syndrome. Contraindicated.Monitor Closely (1)ziprasidone and amoxapine both increase sedation. Use Caution/Monitor.Serious - Use Alternative (1)amoxapine and ziprasidone both increase QTc interval. Avoid or Use Alternate Drug.zolmitriptanMonitor Closely (1)zolmitriptan and amoxapine both increase serotonin levels. Modify Therapy/Monitor Closely.zolpidemMinor (1)zolpidem, amoxapine. Either increases effects of the other by pharmacodynamic synergism. Minor/Significance Unknown. Additive CNS depression. >10% Constipation (12-14%) Dry mouth (12-14%) Sedation (12-14%) 1-10% Anxiety Ataxia Blurred vision Confusion Dizziness Edema Headache Fatigue Nausea Nervousness/restlessness Prolactin levels increased Rash Sweating Tremor Weakness <1% Agranulocytosis Diarrhea ECG changes EPS Flatulence Galactorrhea Hypertension Leukopenia Menstrual irregularity Mydriasis Orthostatic hypotension Seizure Urinary retention Urticaria Vomiting Tachycardia Sexual dysfunction Frequency Not Defined neuroleptic malignant syndrome (rare) Black Box Warnings In short-term studies, antidepressants increased the risk of suicidal thinking and behavior in children, adolescents, and young adults (<24 yr of age) taking antidepressants for major depressive disorders and other psychiatric illnesses This increase was not seen in patients aged >24 years; a slight decrease in suicidal thinking was seen in adults >65 years In children and young adults, risks must be weighed against the benefits of taking antidepressants Patients should be monitored closely for changes in behavior, clinical worsening, and suicidal tendencies; this should be done during initial 1-2 months of therapy and dosage adjustments The patient’s family should communicate any abrupt changes in behavior to the healthcare provider Worsening behavior and suicidal tendencies that are not part of the presenting symptoms may require discontinuation of therapy This drug is not approved for use in pediatric patientsContraindications Hypersensitivity Severe cardiovascular d/o Uncorrected narrow angle glaucoma Within 14 day of MAOIs (risk of serotonin syndrome); if linezolid or IV methylene blue (MAOIs) must be administered, discontinue serotonergic drug immediately and monitor for CNS toxicity; may resume 24 hr after last linezolid or methylene blue dose, or after 2 weeks of monitoring, whichever comes first Any drugs or conditions that prolong QT interval Acute recovery post-MI Cautions BPH, urinary/GI retention, incr IOP,